e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
COPD treatment and others
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Does the 2011 GOLD staging of COPD reflect phenotype and severity of the disease as assessed by CT?
F. Bigazzi, M. Paoletti, E. Torricelli, V. Luzzi, A. Garcea, M. Vannini, L. Corsi, V. Bellino, L. Cestelli, G. Camiciottoli, M. Pistolesi (Florence, Italy)
Source:
Annual Congress 2013 –COPD treatment and others
Session:
COPD treatment and others
Session type:
Thematic Poster Session
Number:
3656
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Bigazzi, M. Paoletti, E. Torricelli, V. Luzzi, A. Garcea, M. Vannini, L. Corsi, V. Bellino, L. Cestelli, G. Camiciottoli, M. Pistolesi (Florence, Italy). Does the 2011 GOLD staging of COPD reflect phenotype and severity of the disease as assessed by CT?. Eur Respir J 2013; 42: Suppl. 57, 3656
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Evaluation of the GOLD 2011 severity criteria across the COPD spectrum
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
COPD: GOLD 2011 and implications for clinical practice
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Frequency and severity of exacerbations reflect COPD severity, but not COPD phenotype as determined by quantitative CT
Source: International Congress 2014 – Markers
Year: 2014
GOLD staging and grading for predicting one-year mortality in COPD patients with severe exacerbation
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Three year follow-up of distribution and stability of patients with COPD according GOLD 2014
Source: International Congress 2015 – Clinical assessment in asthma and COPD
Year: 2015
Heterogeneity of group D in the new GOLD classification of COPD
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
COPD comorbidities and risk assessment according to GOLD 2011 revision
Source: Annual Congress 2013 –Monitoring respiratory diseases: role of comorbidities and lung involvement
Year: 2013
Severity of airflow obstruction and multicomponent disease staging of COPD in the real-world primary care in Greece: The AEOLUS study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Cardiovascular comorbidities prevails in the early stages of COPD irrespective of predominant airway or emphysema phenotype
Source: Annual Congress 2013 –COPD treatment
Year: 2013
The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
GOLD and phenotypes: The new Czech COPD guidelines
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Significance of quantitative radiological phenotypes of COPD on BODE index
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
The relationship between presence of small airways disease and baseline characteristics of asthma and COPD patients
Source: International Congress 2016 – Monitoring airway diseases with different tools
Year: 2016
To study the severity of lung hyperinflation and bone mineral density in patients with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Detection of chronic obstructive pulmonary disease (COPD) in patients with cardio-vascular system pathology
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Are there any differences between Tunisian and European COPD phenotypes?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016
Pulmonary diffusing capacity and the risk of fractures in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – COPD markers
Year: 2014
Clinical and inflammatory characteristics of 'unreported' COPD exacerbations
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Can we personalize COPD treatment by exacerbation frequency and severity? Three years of follow-up
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
Early phenotypes of chronic obstructive pulmonary disease (COPD)
Source: International Congress 2015 – Different data in COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept